Neogen Corporation

NEOG Healthcare Medical Devices

Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.

Revenue
+6.50%
EPS
−129.4%
Free cash flow
+135.6%
Total debt
−2.31%

Quarter to August 2026, against a year earlier

11.77 0.09 +0.77%
Market cap
$2.6B
P/E
0.0×
Fwd P/E
−93.3×
Dividend yield
—
F-score
5/9
Altman Z
1.11
Beneish M
−2.43
Dividend safety
n/a

Neogen Corporation (NEOG) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Neogen Corporation (NEOG) trades at a P/B ratio of 1.2×. Over the past ten years it has ranged from 0.4× (April 2025) to 8.6× (September 2018); the current reading is higher than 26% of that period. That is below the Medical Devices industry median of 2.5× and below the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2026 0.9× 55.56%
FY2025 0.6× (34.19%)
FY2024 0.9× (14.09%)
FY2023 1.1× (67.18%)
FY2022 3.2× (44.46%)
FY2021 5.8× 11.05%
FY2020 5.2× 13.56%
FY2019 4.6× (33.96%)
FY2018 6.9× 36.53%
FY2017 5.1× 11.26%

Quarterly newest first

Period P/B ratio Change
Aug 2026 1.2× 30.36%
May 2026 0.9× (19.71%)
Feb 2026 1.2× 88.78%
Nov 2025 0.6× 5.78%
43 more quarters

Against its own ten years

Low 0.4× High 8.6×
Ten-year median 4.9×
Current reading's percentile 28

P/B ratio against peers

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on NEOG